Pharmaceutical versions come in pre-filled pens that automatically dose correctly
The medication improves insulin secretion, reduces glucagon release, and slows gastric emptying, allowing for better glycaemic control when carbohydrates are consumed
It gives manageable injection volumes for standard doses
Recent Findings Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia
An additional hypothesis is that direct beta-cell to alfa-cell communication could be responsible for the glucagonostatic effect of GLP-1
Conversely, evening or night-time administration may suit those who find that initial post-injection nausea is better tolerated during sleep